Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE: RDY), along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Tadalafil Tablets USP, a therapeutic equivalent generic version of Adcirca (tadalafil) Tablets in the United States market, approved by the U.S. Food and Drug Administration (USFDA).
The Adcirca brand and generic had U.S. sales of approximately $490 million MAT for the most recent twelve months ending in November 2018 according to IMS Health*.
Dr. Reddy's Tadalafil Tablets are available in 20 mg with 60 count bottle size. Adcirca is a trademark of Eli Lilly and Company.
Shares of DR.REDDY'S LABORATORIES LTD. was last trading in BSE at Rs.2616.95 as compared to the previous close of Rs. 2772.3. The total number of shares traded during the day was 112735 in over 7111 trades.
The stock hit an intraday high of Rs. 2704.7 and intraday low of 2555.55. The net turnover during the day was Rs. 295553014.
*IMS National Sales Perspective: Retail and Non-Retail MAT November 2018